Top

Published in:

01-08-2012

Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

Authors: Wenchao Hu, Qian Yu, Jie Zhang, Demin Liu

Published in: Inflammation | Issue 4/2012

Abstract

Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. This study aims to determine whether rosiglitazone and pioglitazone ameliorate renal function through an effect on the expression of chemerin and ChemR23 in streptozotocin-induced diabetic rats. The rats were randomized to control, diabetic, rosiglitazone-, and pioglitazone-treated groups. The expression level of chemerin and ChemR23 in the renal tissues was significantly elevated in the diabetic group compared with the control group. Rosiglitazone inhibited the overexpression of chemerin and ChemR23, while pioglitazone inhibited the overexpression of ChemR23 in the kidney of diabetic rats. In addition, chemerin expression level was positively correlated with transforming growth factor-β1, connective tissue growth factor, tumor necrosis factor-α, and intracellular cell adhesion molecule-1 expression in diabetic rats. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats.

Wagman, A.S., and J.M. Nuss. 2001. Current therapies and emerging targets for the treatment of diabetes. Current Pharmaceutical Design 7(6): 417–450.PubMedCrossRef

Pfau, D., A. Bachmann, U. Lössner, J. Kratzsch, M. Blüher, M. Stumvoll, and M. Fasshauer. 2010. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 33(1): 171–173.PubMedCrossRef

Yamamoto, T., A.R. Qureshi, B. Anderstam, O. Heimbürger, P. Bárány, B. Lindholm, P. Stenvinkel, and J. Axelsson. 2010. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrology, Dialysis, Transplantation 25(12): 4017–4023.PubMedCrossRef

Hu, W., and P. Feng. 2010. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Research and Clinical Practice 91(2): 159–163.PubMedCrossRef

Lehrke, M., A. Becker, M. Greif, R. Stark, R.P. Laubender, F. von Ziegler, C. Lebherz, J. Tittus, M. Reiser, C. Becker, B. Göke, A.W. Leber, K.G. Parhofer, and U.C. Broedl. 2009. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. European Journal of Endocrinology 161(2): 339–344.PubMedCrossRef

Weigert, J., M. Neumeier, J. Wanninger, M. Filarsky, S. Bauer, R. Wiest, S. Farkas, M.N. Scherer, A. Schäffler, C. Aslanidis, J. Schölmerich, and C. Buechler. 2010. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clinical Endocrinology 72(3): 342–348.PubMedCrossRef

King, G.L. 2008. The role of inflammatory cytokines in diabetes and its complications. Journal of Periodontology 79(8 Suppl): 1527–1534.PubMedCrossRef

Roh, S.G., S.H. Song, K.C. Choi, K. Katoh, V. Wittamer, M. Parmentier, and S. Sasaki. 2007. Chemerin–a new adipokine that modulates adipogenesis via its own receptor. Biochemical and Biophysical Research Communications 362(4): 1013–1038.PubMedCrossRef

Yoshimura, T., and J.J. Oppenheim. 2011. Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties. Experimental Cell Research 317(5): 674–684.PubMedCrossRef

10.

Lebovitz, H.E., and M.A. Banerji. 2001. Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Hormone Research 56: 265–294.PubMedCrossRef

11.

Zheng, M., S. Ye, Z. Zhai, Y. Chen, X. Li, G. Yang, A. Fan, and Y. Wang. 2009. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. Journal of Diabetes and its Complications 23(2): 124–129.PubMedCrossRef

12.

Kim, H.J., S.K. Kim, W.S. Shim, J.H. Lee, K.Y. Hur, E.S. Kang, C.W. Ahn, S.K. Lim, H.C. Lee, and B.S. Cha. 2008. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 81(1): 42–49.PubMedCrossRef

13.

Majuri, A., M. Santaniemi, K. Rautio, A. Kunnari, J. Vartiainen, A. Ruokonen, Y.A. Kesäniemi, J.S. Tapanainen, O. Ukkola, and L. Morin-Papunen. 2007. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study. European Journal of Endocrinology 156(2): 263–269.PubMedCrossRef

14.

Aso, Y., K. Hara, N. Ozeki, C. Yatsuka, T. Nakano, S. Matsumoto, M. Suetsugu, T. Nakamachi, K. Takebayashi, K. Haruki, and T. Inukai. 2009. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Research and Clinical Practice 85(2): 147–152.PubMedCrossRef

15.

Pfützner, A., N. Marx, D. Walcher, M. Löbig, D. Seidel, and T. Forst. 2008. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clinical Laboratory 54(7–8): 237–241.PubMed

16.

Goralski, K.B., T.C. McCarthy, E.A. Hanniman, B.A. Zabel, E.C. Butcher, S.D. Parlee, S. Muruganandan, and C.J. Sinal. 2007. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. Journal of Biological Chemistry 282(38): 28175–28188.PubMedCrossRef

17.

Stejskal, D., M. Karpisek, Z. Hanulova, and M. Svestak. 2008. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152(2): 217–221.PubMed

18.

Bozaoglu, K., D. Segal, K.A. Shields, N. Cummings, J.E. Curran, A.G. Comuzzie, M.C. Mahaney, D.L. Rainwater, J.L. VandeBerg, J.W. MacCluer, G. Collier, J. Blangero, K. Walder, and J.B. Jowett. 2009. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. Journal of Clinical Endocrinology and Metabolism 94(8): 3085–3088.PubMedCrossRef

19.

Derosa, G., and P. Maffioli. 2011. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Research and Clinical Practice 91(3): 265–270.PubMedCrossRef

20.

Sarafidis, P.A., P.C. Stafylas, P.I. Georgianos, A.N. Saratzis, and A.N. Lasaridis. 2010. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. American Journal of Kidney Diseases 55(5): 835–847.PubMedCrossRef

21.

Toblli, J.E., G. Cao, J.F. Giani, M. Angerosa, F.P. Dominici, and N.F. Gonzalez-Cadavid. 2011. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney & Blood Pressure Research 34(1): 20–33.CrossRef

22.

Muruganandan, S., S.D. Parlee, J.L. Rourke, M.C. Ernst, K.B. Goralski, and C.J. Sinal. 2011. Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis. Journal of Biological Chemistry 286(27): 23982–23995.PubMedCrossRef

23.

Han, D.C., B.B. Hoffman, S.W. Hong, J. Guo, and F.N. Ziyadeh. 2000. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. American Journal of Physiology. Renal Physiology 278: F628–F634.PubMed

24.

Yamamoto, T., T. Nakamura, N.A. Noble, E. Ruoslahti, and W.A. Border. 1993. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America 90(5): 1814–1818.PubMedCrossRef

25.

Connolly, S.B., D. Sadlier, N.E. Kieran, P. Doran, and H.R. Brady. 2003. Transcriptome profiling and the pathogenesis of diabetic complications. Journal of the American Society of Nephrology 14: S279–S283.PubMedCrossRef

26.

Wahab, N.A., L. Schaefer, B.S. Weston, O. Yiannikouris, A. Wright, A. Babelova, R. Schaefer, and R.M. Mason. 2005. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48(12): 2650–2660.PubMedCrossRef

27.

Yeo, E.S., J.Y. Hwang, J.E. Park, Y.J. Choi, K.B. Huh, and W.Y. Kim. 2010. Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Medical Journal 51(4): 519–525.PubMedCrossRef

28.

Chen, L., J. Zhang, Y. Zhang, Y. Wang, and B. Wang. 2008. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflammation Research 57(5): 199–204.PubMedCrossRef

29.

Chow, F.Y., D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, and G.H. Tesch. 2005. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. Journal of the American Society of Nephrology 16(6): 1711–1722.PubMedCrossRef

30.

Hart, R., and D.R. Greaves. 2010. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. Journal of Immunology 185(6): 3728–3739.CrossRef

31.

Sell, H., A. Divoux, C. Poitou, A. Basdevant, J.L. Bouillot, P. Bedossa, J. Tordjman, J. Eckel, and K. Clément. 2010. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 95(6): 2892–2896.PubMedCrossRef

Title: Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats
Authors: Wenchao Hu
Qian Yu
Jie Zhang
Demin Liu
Publication date: 01-08-2012
Publisher: Springer US
Published in: Inflammation / Issue 4/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-012-9440-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Bacterial Cell Wall Constituents Induce Hepcidin Expression in Macrophages Through MyD88 Signaling

Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study

The Functional Interaction Between CDK11p58 and β-1,4-Galactosyltransferase I Involved in Astrocyte Activation Caused by Lipopolysaccharide

Association of MicroRNA-146a with Autoimmune Diseases

High Levels of Inflammation and Insulin Resistance in Obstructive Sleep Apnea Patients with Hypertension

Lipopolysaccharide-Induced Proliferation of the Vasa Vasorum in a Rabbit Model of Atherosclerosis as Evaluated by Contrast-Enhanced Ultrasound Imaging and Histology

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page